Memphis Pharmaceuticals & Chemical Industries produces and sells pharmaceutical products for human and veterinary use in Egypt.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م23.01|
|52 Week High||ج.م14.20|
|52 Week Low||ج.م34.98|
|1 Month Change||-15.19%|
|3 Month Change||-19.55%|
|1 Year Change||52.79%|
|3 Year Change||182.68%|
|5 Year Change||131.49%|
|Change since IPO||-23.86%|
Recent News & Updates
|MPCI||EG Pharmaceuticals||EG Market|
Return vs Industry: MPCI exceeded the EG Pharmaceuticals industry which returned -0.9% over the past year.
Return vs Market: MPCI exceeded the EG Market which returned 9.2% over the past year.
Stable Share Price: MPCI is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MPCI's weekly volatility (5%) has been stable over the past year.
About the Company
Memphis Pharmaceuticals & Chemical Industries produces and sells pharmaceutical products for human and veterinary use in Egypt. The company offers human health products in various therapeutic areas, including anti-infective, CNS, dermatological, cardio vascular system, corticosteroid, vitamins and minerals, musculo-skeletal system, analgesic and antipyretic, respiratory system, genitourinary system, alimentary tract and metabolism, antihistaminic, antiparasites, and hormones. It also provides animal health products in powder form, as well as in oral and injectable solution forms.
Memphis Pharmaceuticals & Chemical Industries Fundamentals Summary
|MPCI fundamental statistics|
Is MPCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MPCI income statement (TTM)|
|Cost of Revenue||ج.م394.34m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||6.68|
|Net Profit Margin||7.43%|
How did MPCI perform over the long term?See historical performance and comparison
Is Memphis Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MPCI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MPCI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MPCI is good value based on its PE Ratio (3.4x) compared to the EG Pharmaceuticals industry average (5.9x).
PE vs Market: MPCI is good value based on its PE Ratio (3.4x) compared to the EG market (11.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MPCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MPCI has negative assets, so we can't compare its PB Ratio to the EG Pharmaceuticals industry average.
How is Memphis Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Memphis Pharmaceuticals & Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Memphis Pharmaceuticals & Chemical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MPCI has high quality earnings.
Growing Profit Margin: MPCI became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MPCI has become profitable over the past 5 years, growing earnings by 27.7% per year.
Accelerating Growth: MPCI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MPCI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).
Return on Equity
High ROE: MPCI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Memphis Pharmaceuticals & Chemical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: MPCI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MPCI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MPCI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MPCI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: MPCI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: MPCI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Memphis Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MPCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MPCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MPCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MPCI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MPCI is not paying a notable dividend for the EG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MPCI's dividend in 3 years as they are not forecast to pay a notable one for the EG market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Memphis Pharmaceuticals & Chemical Industries has no CEO, or we have no data on them.
Experienced Management: MPCI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Memphis Pharmaceuticals & Chemical Industries's employee growth, exchange listings and data sources
- Name: Memphis Pharmaceuticals & Chemical Industries
- Ticker: MPCI
- Exchange: CASE
- Founded: 1940
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م129.431m
- Shares outstanding: 5.63m
- Website: https://www.memphis.com.eg
Number of Employees
- Memphis Pharmaceuticals & Chemical Industries
- 7 Fadhli Street
- St. Talaat Harb
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 14:31|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.